UY29326A1 - Metodo de tratamiento - Google Patents
Metodo de tratamientoInfo
- Publication number
- UY29326A1 UY29326A1 UY29326A UY29326A UY29326A1 UY 29326 A1 UY29326 A1 UY 29326A1 UY 29326 A UY29326 A UY 29326A UY 29326 A UY29326 A UY 29326A UY 29326 A1 UY29326 A1 UY 29326A1
- Authority
- UY
- Uruguay
- Prior art keywords
- limited
- similar
- treatment method
- personality
- pheniclidine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Abstract
Método para tratar al menos síntoma o afección asociado con, pero sin limitarse, a trastornos relacionados con: - sustancias incluyendo pero sin limitarse a dependencia, abuso, intoxicación y abstinencia a sustancias - Alcohol, Anfetaminas (Similares), Cafeína, Cannabis, Cocaína, Halucinógenos, Inhalables - Nicotina, Opioides, Feniclidina (similares),Sedativos, Hipnóticos o Ansiolíticos. - déficit Atencional y Comportamiento Errático. - hábitos alimenticios. - personalidad incluyendo pero sin limitarse a trastorno de Personalidad Obsesivo-Compulsivo. - control de Impulsos, comprendiendo administración de cantidad eficaz de Fórmula I.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64226205P | 2005-01-07 | 2005-01-07 | |
US73786405P | 2005-11-18 | 2005-11-18 | |
US73786505P | 2005-11-18 | 2005-11-18 | |
US73788705P | 2005-11-18 | 2005-11-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY29326A1 true UY29326A1 (es) | 2006-08-31 |
Family
ID=36647771
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY29326A UY29326A1 (es) | 2005-01-07 | 2006-01-05 | Metodo de tratamiento |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1838325A1 (es) |
JP (1) | JP2008526839A (es) |
AR (1) | AR052191A1 (es) |
TW (1) | TW200640466A (es) |
UY (1) | UY29326A1 (es) |
WO (1) | WO2006073360A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090069292A1 (en) * | 2005-11-18 | 2009-03-12 | Astrazeneca Ab | Liquid Formulations |
ME01516B (me) | 2008-06-20 | 2014-04-20 | Astrazeneca Ab | DERIVAT DIBENZOTIAZEPINA l NJEGOVA UPOTREBA |
US8389716B2 (en) | 2009-01-30 | 2013-03-05 | F.I.S. Fabbrica Italiana Sintetici S.P.A. | Process for the synthesis of quetiapine |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3539573A (en) * | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
GB8607684D0 (en) * | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
US7071133B2 (en) * | 1993-11-16 | 2006-07-04 | Ppg Industries Ohio, Inc. | Colored glass compositions and-automotive vision panels with-reduced transmitted-color shift |
US5602124A (en) * | 1994-12-12 | 1997-02-11 | Allelix Biopharmaceuticals, Inc. | 5-HT2 receptor ligands |
SE0003126D0 (sv) * | 2000-09-05 | 2000-09-05 | Astrazeneca Ab | Method of treatment |
JP2004518699A (ja) * | 2001-02-06 | 2004-06-24 | アストラゼネカ・アクチエボラーグ | クエチアピンを用いた物質乱用の治療方法 |
EP1578428A4 (en) * | 2002-10-18 | 2008-11-26 | Massachusetts Mental Health In | TREATMENT OF ALCOHOL OR DRUG ABUSE BY ANTAGONIZING ALPHA-A2 DRENERGEN RECEPTORS WITH SWITCHING DOPAMINE BLOCKING |
CN1816339B (zh) * | 2003-07-02 | 2010-12-15 | 阿斯利康(瑞典)有限公司 | 喹硫平的代谢物 |
WO2005053619A2 (en) * | 2003-12-04 | 2005-06-16 | The Research Foundation Of The City University Of New York | Clozapine and cocaine effects on dopamine and serotonin release in nucleus accumbens during psychostimulant behavior and withdrawal |
SI1696931T1 (sl) * | 2003-12-22 | 2009-08-31 | Acadia Pharm Inc | Amino substituirani diaril(a,d)cikloheptenski analogi kot muskarinski agonisti in postopki za zdravljenje nevropsihiatričnih motenj |
US20050171088A1 (en) * | 2004-01-30 | 2005-08-04 | Astrazeneca Ab | Treatment of psychoses with dibenzothiazepine antipsychotic |
-
2006
- 2006-01-04 JP JP2007550327A patent/JP2008526839A/ja active Pending
- 2006-01-04 EP EP06700349A patent/EP1838325A1/en not_active Withdrawn
- 2006-01-04 WO PCT/SE2006/000009 patent/WO2006073360A1/en active Application Filing
- 2006-01-05 UY UY29326A patent/UY29326A1/es not_active Application Discontinuation
- 2006-01-06 AR ARP060100058A patent/AR052191A1/es not_active Application Discontinuation
- 2006-01-06 TW TW095100687A patent/TW200640466A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
TW200640466A (en) | 2006-12-01 |
JP2008526839A (ja) | 2008-07-24 |
AR052191A1 (es) | 2007-03-07 |
EP1838325A1 (en) | 2007-10-03 |
WO2006073360A1 (en) | 2006-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008036846A3 (en) | Combination comprising an hmg-coa reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis | |
EP2698166A3 (en) | Complement inhibition for improved nerve regeneration | |
WO2008036678A3 (en) | Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis | |
EA200901166A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr 119 | |
WO2007030697A3 (en) | Modulation of neurogenesis by hdac inhibition | |
WO2006131952A8 (en) | Novel analgesic treatment with prolonged effect | |
TN2010000122A1 (en) | Compounds and compositions as modulators of gpr119 activity | |
WO2007022506A3 (en) | Methods and compositions for treating neurological disease | |
TW200740804A (en) | Glucokinase activators | |
WO2005116088A3 (en) | Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells | |
MA31767B1 (fr) | Composes organiques et leurs utilisations | |
WO2007056457A3 (en) | Methods, compositions, and kits for the treatment of medical conditions | |
WO2007134077A3 (en) | 5 ht receptor mediated neurogenesis | |
WO2008039863A3 (en) | Composition comprising a melanocortin receptor (mcr) modulating agent alone or in combination with a second neurogenic agent for treating nervous system disorders | |
WO2009052431A3 (en) | Cd19 binding agents and uses thereof | |
WO2007103114A3 (en) | Notch inhibition in the treatment or prevention of atherosclerosis | |
WO2007109330A3 (en) | S1p receptor modulating compounds | |
WO2007095586A3 (en) | Neuronal pain pathway modulators | |
WO2007024971A3 (en) | Hedgehog pathway antagonists to treat disease | |
WO2010017436A3 (en) | Modulation of myeloid differentation primary response gene 88 (myd88) expression by antisense oligonucleotides | |
MA33241B1 (fr) | Composes pour le traitement de troubles metaboliques | |
MA33190B1 (fr) | Composes pour le traitement de troubles metaboliques | |
ATE542535T1 (de) | Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten | |
WO2009130600A8 (en) | Therapeutic use of at least one botulinum neurotoxin in the treatment of pain associated with diabetic neuropathy | |
WO2006039343A3 (en) | Emmprin antagonists and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20160725 |